This is a bone marrow transplant study for patients with neuroblastoma who have either advanced disease or relapsed neuroblastoma. Only pediatric patients (those < 18 years of age) will be eligible. Patients will be entered on this trial to determine the maximum dose of 131-I MIBG that can be given in combination with chemotherapy (Carboplatin, Etoposide, and Melphalan) for bone marrow transplantation for neuroblastoma. Historically, autologous bone marrow transplants for neuroblastoma have utilized total body irradiation in combination with intensive chemotherapy as conditioning therapy. This protocol utilizes a radioactive compound, 131-I MIBG, instead of total body irradiation in the transplant process for patients with neuroblastoma.
Showing the most recent 10 out of 1380 publications